We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ascendis Pharma AS (ASND) ADR

Sell:$124.00 Buy:$146.54 Change: $7.17 (5.85%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$124.00
Buy:$146.54
Change: $7.17 (5.85%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$124.00
Buy:$146.54
Change: $7.17 (5.85%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Contact details

Address:
Tuborg Boulevard 12
HELLERUP
2900
Denmark
Telephone:
+45 (702) 22244
Website:
https://ascendispharma.dk/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ASND
ISIN:
US04351P1012
Market cap:
$7.54 billion
Shares in issue:
60.64 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jan Moller Mikkelsen
    President, Chief Executive Officer, Executive Director, Member of the Executive Board
  • Scott Smith
    Chief Financial Officer, Executive Vice President, Member of the Executive Board
  • Lotte Soenderbjerg
    Executive Vice President, Chief Administrative Officer
  • Camilla Hartvig
    Executive Vice President, Global Chief Commercial Officer
  • Flemming Jensen
    Executive Vice President, Product Supply and Quality
  • Michael Jensen
    Executive Vice President, Chief Legal Officer
  • Stina Singel
    Executive Vice President, Head of Clinical Development, Oncology
  • Kennett Sprogoee
    Executive Vice President, Head of Innovation and Research
  • Peter Rasmussen
    Principal Accounting Officer, Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.